Roche bags breakthrough status for autism hope balovaptan

Roche has been awarded breakthrough status for a drug that has shown some signs of activity in autism spectrum disorders, according to reports.

Balovaptan (RG7314) aims to treat autism by modulating the activity of vasopressin, a hormone that first emerged as a possible drug target in the disorder a few years ago. It blocks the activity of the V1a vasopressin receptor subtype and is currently in phase 2 testing.

Reuters said this morning that the FDA granted breakthrough status to the program in the hope of accelerating its progress through development and onto the market.

Read Full Item
29th January 2018
Fierce Biotech